Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in the treatment of peritoneal carcinomatosis

David C. Gammon, Traci Dutton, Bilal Piperdi, Jason Zybert, Steven H. Wolfe, Erin Nguyen, Dalia Sbat, Venu G. Pillarisetty, Mary Sullivan, Giles F. Whalen

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose. Cytoreductive surgery (CS) and intraperitoneal hyperthermic chemotherapy (IPHC) in the treatment of peritoneal carcinomatosis (PC) in 15 patients are described. Summary. Fifteen patients with PC who were treated with CS and IPHC were retrospectively identified between January 2002 and December 2006. All patients underwent cytoreduction immediately followed by IPHC with mitomycin or cisplatin. The time between undergoing CS and IPHC and the date of the last follow-up appointment or the date of death was used to calculate survival data for each patient. Nine patients had complete cytoreduction, and all but one patient had evidence of invasive disease at the time of surgery. Eleven patients required concomitant bowel resection at the time of debulking. Thirteen patients required blood transfusions during the perioperative period. Nine patients were discharged home, and four were discharged to a rehabilitation facility. Two patients died during the perioperative hospital admission, both of whom had a preoperative Eastern Cooperative Oncology Group (ECOG) performance status score of 2. The median survival time was 8.4 months, similar to the findings of previously published studies. Further studies are needed to see if tumor type, ECOG performance status score, degree of cytoreduction, and the chemotherapy agent used in IPHC can be correlated to quality of life and survival in patients with heterogeneous primary sources of intraabdominal malignancies. Conclusion. Combination treatment with CS followed by IPHC in 15 patients with heterogeneous primary sources of intraabdominal malignancies resulted in a median survival time of 8.4 months.

Original languageEnglish (US)
Pages (from-to)1186-1190
Number of pages5
JournalAmerican Journal of Health-System Pharmacy
Volume66
Issue number13
DOIs
StatePublished - Jul 1 2009
Externally publishedYes

Fingerprint

Carcinoma
Drug Therapy
Therapeutics
Survival
Neoplasms
Perioperative Period
Mitomycin
Blood Transfusion
Cisplatin
Appointments and Schedules
Rehabilitation
Quality of Life

Keywords

  • Antineoplastic agents
  • Cisplatin
  • Hyperthermia
  • Mitomycin
  • Peritoneal neoplasms
  • Quality of life
  • Surgery

ASJC Scopus subject areas

  • Pharmacology
  • Health Policy
  • Medicine(all)

Cite this

Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in the treatment of peritoneal carcinomatosis. / Gammon, David C.; Dutton, Traci; Piperdi, Bilal; Zybert, Jason; Wolfe, Steven H.; Nguyen, Erin; Sbat, Dalia; Pillarisetty, Venu G.; Sullivan, Mary; Whalen, Giles F.

In: American Journal of Health-System Pharmacy, Vol. 66, No. 13, 01.07.2009, p. 1186-1190.

Research output: Contribution to journalArticle

Gammon, DC, Dutton, T, Piperdi, B, Zybert, J, Wolfe, SH, Nguyen, E, Sbat, D, Pillarisetty, VG, Sullivan, M & Whalen, GF 2009, 'Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in the treatment of peritoneal carcinomatosis', American Journal of Health-System Pharmacy, vol. 66, no. 13, pp. 1186-1190. https://doi.org/10.2146/ajhp080019
Gammon, David C. ; Dutton, Traci ; Piperdi, Bilal ; Zybert, Jason ; Wolfe, Steven H. ; Nguyen, Erin ; Sbat, Dalia ; Pillarisetty, Venu G. ; Sullivan, Mary ; Whalen, Giles F. / Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in the treatment of peritoneal carcinomatosis. In: American Journal of Health-System Pharmacy. 2009 ; Vol. 66, No. 13. pp. 1186-1190.
@article{2ec15586b9c6416eb16b886962697c9a,
title = "Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in the treatment of peritoneal carcinomatosis",
abstract = "Purpose. Cytoreductive surgery (CS) and intraperitoneal hyperthermic chemotherapy (IPHC) in the treatment of peritoneal carcinomatosis (PC) in 15 patients are described. Summary. Fifteen patients with PC who were treated with CS and IPHC were retrospectively identified between January 2002 and December 2006. All patients underwent cytoreduction immediately followed by IPHC with mitomycin or cisplatin. The time between undergoing CS and IPHC and the date of the last follow-up appointment or the date of death was used to calculate survival data for each patient. Nine patients had complete cytoreduction, and all but one patient had evidence of invasive disease at the time of surgery. Eleven patients required concomitant bowel resection at the time of debulking. Thirteen patients required blood transfusions during the perioperative period. Nine patients were discharged home, and four were discharged to a rehabilitation facility. Two patients died during the perioperative hospital admission, both of whom had a preoperative Eastern Cooperative Oncology Group (ECOG) performance status score of 2. The median survival time was 8.4 months, similar to the findings of previously published studies. Further studies are needed to see if tumor type, ECOG performance status score, degree of cytoreduction, and the chemotherapy agent used in IPHC can be correlated to quality of life and survival in patients with heterogeneous primary sources of intraabdominal malignancies. Conclusion. Combination treatment with CS followed by IPHC in 15 patients with heterogeneous primary sources of intraabdominal malignancies resulted in a median survival time of 8.4 months.",
keywords = "Antineoplastic agents, Cisplatin, Hyperthermia, Mitomycin, Peritoneal neoplasms, Quality of life, Surgery",
author = "Gammon, {David C.} and Traci Dutton and Bilal Piperdi and Jason Zybert and Wolfe, {Steven H.} and Erin Nguyen and Dalia Sbat and Pillarisetty, {Venu G.} and Mary Sullivan and Whalen, {Giles F.}",
year = "2009",
month = "7",
day = "1",
doi = "10.2146/ajhp080019",
language = "English (US)",
volume = "66",
pages = "1186--1190",
journal = "American Journal of Health-System Pharmacy",
issn = "1079-2082",
publisher = "American Society of Health-Systems Pharmacy",
number = "13",

}

TY - JOUR

T1 - Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in the treatment of peritoneal carcinomatosis

AU - Gammon, David C.

AU - Dutton, Traci

AU - Piperdi, Bilal

AU - Zybert, Jason

AU - Wolfe, Steven H.

AU - Nguyen, Erin

AU - Sbat, Dalia

AU - Pillarisetty, Venu G.

AU - Sullivan, Mary

AU - Whalen, Giles F.

PY - 2009/7/1

Y1 - 2009/7/1

N2 - Purpose. Cytoreductive surgery (CS) and intraperitoneal hyperthermic chemotherapy (IPHC) in the treatment of peritoneal carcinomatosis (PC) in 15 patients are described. Summary. Fifteen patients with PC who were treated with CS and IPHC were retrospectively identified between January 2002 and December 2006. All patients underwent cytoreduction immediately followed by IPHC with mitomycin or cisplatin. The time between undergoing CS and IPHC and the date of the last follow-up appointment or the date of death was used to calculate survival data for each patient. Nine patients had complete cytoreduction, and all but one patient had evidence of invasive disease at the time of surgery. Eleven patients required concomitant bowel resection at the time of debulking. Thirteen patients required blood transfusions during the perioperative period. Nine patients were discharged home, and four were discharged to a rehabilitation facility. Two patients died during the perioperative hospital admission, both of whom had a preoperative Eastern Cooperative Oncology Group (ECOG) performance status score of 2. The median survival time was 8.4 months, similar to the findings of previously published studies. Further studies are needed to see if tumor type, ECOG performance status score, degree of cytoreduction, and the chemotherapy agent used in IPHC can be correlated to quality of life and survival in patients with heterogeneous primary sources of intraabdominal malignancies. Conclusion. Combination treatment with CS followed by IPHC in 15 patients with heterogeneous primary sources of intraabdominal malignancies resulted in a median survival time of 8.4 months.

AB - Purpose. Cytoreductive surgery (CS) and intraperitoneal hyperthermic chemotherapy (IPHC) in the treatment of peritoneal carcinomatosis (PC) in 15 patients are described. Summary. Fifteen patients with PC who were treated with CS and IPHC were retrospectively identified between January 2002 and December 2006. All patients underwent cytoreduction immediately followed by IPHC with mitomycin or cisplatin. The time between undergoing CS and IPHC and the date of the last follow-up appointment or the date of death was used to calculate survival data for each patient. Nine patients had complete cytoreduction, and all but one patient had evidence of invasive disease at the time of surgery. Eleven patients required concomitant bowel resection at the time of debulking. Thirteen patients required blood transfusions during the perioperative period. Nine patients were discharged home, and four were discharged to a rehabilitation facility. Two patients died during the perioperative hospital admission, both of whom had a preoperative Eastern Cooperative Oncology Group (ECOG) performance status score of 2. The median survival time was 8.4 months, similar to the findings of previously published studies. Further studies are needed to see if tumor type, ECOG performance status score, degree of cytoreduction, and the chemotherapy agent used in IPHC can be correlated to quality of life and survival in patients with heterogeneous primary sources of intraabdominal malignancies. Conclusion. Combination treatment with CS followed by IPHC in 15 patients with heterogeneous primary sources of intraabdominal malignancies resulted in a median survival time of 8.4 months.

KW - Antineoplastic agents

KW - Cisplatin

KW - Hyperthermia

KW - Mitomycin

KW - Peritoneal neoplasms

KW - Quality of life

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=70349259376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349259376&partnerID=8YFLogxK

U2 - 10.2146/ajhp080019

DO - 10.2146/ajhp080019

M3 - Article

C2 - 19535657

AN - SCOPUS:70349259376

VL - 66

SP - 1186

EP - 1190

JO - American Journal of Health-System Pharmacy

JF - American Journal of Health-System Pharmacy

SN - 1079-2082

IS - 13

ER -